Albireo Pharma, Inc. (ALBO)

Market Cap	367.73M
Revenue (ttm)	51.22M
Net Income (ttm)	-36.26M
Shares Out	19.61M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,950
Open	19.50
Previous Close	19.36
Day's Range	18.53 - 19.65
52-Week Range	16.02 - 37.63
Beta	0.93
Analysts	Buy
Price Target	55.76 (+197.4%)
Earnings Date	Nov 2, 2022

About ALBO

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other f...

• Industry: Biotechnology
• CEO: Ronald Cooper
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: ALBO

Full Company Profile

Financial Performance

In 2021, Albireo Pharma's revenue was $40.58 million, an increase of 388.43% compared to the previous year's $8.31 million. Losses were -$34.03 million, -68.38% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ALBO stock is "Buy." The 12-month stock price forecast is 55.76, which is an increase of 197.39% from the latest price.

Price Target

$55.76

(197.39% upside)

Analyst Consensus: Buy

Stock Forecasts